Finch Therapeutics Group Inc
Change company Symbol lookup
Select an option...
FNCH Finch Therapeutics Group Inc
TOL Toll Brothers Inc
TGEN Tecogen Inc
EPAM Epam Systems Inc
ISLE Isleworth Healthcare Acquisition Corp
TRMD Torm PLC
THC Tenet Healthcare Corp
BKCC BlackRock Capital Investment Corp
VIR Vir Biotechnology Inc
CBH Virtus Convertible & Income 2024 Target Term Fund
Go

Health Care : Biotechnology | Small Cap Growth

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates.

Price: Delayed
$2.83

Day's Change: -0.05 (-1.74%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.85

Day's Low: 2.80

Volume (Light) Today's volume of 11,051 shares is on pace to be much lighter than FNCH's 10-day average volume of 197,256 shares.: 11,051

June 02, 2022
7:00 am ET	Finch Therapeutics to Participate in Upcoming June Investor Conferences EQNX::TICKER_START (NASDAQ:FNCH), EQNX::TICKER_END Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel...(Globe Newswire)
May 17, 2022
8:00 am ET	Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference EQNX::TICKER_START (NASDAQ:FNCH), EQNX::TICKER_END Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel...(Globe Newswire)
May 16, 2022
7:00 am ET	Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results EQNX::TICKER_START (NASDAQ:FNCH), EQNX::TICKER_END -- Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 -- $15 million drawn from new $55 million term debt facility (Globe Newswire)
May 09, 2022
8:22 am ET	Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022 EQNX::TICKER_START (NASDAQ:FNCH), EQNX::TICKER_END Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel...(Globe Newswire)
April 29, 2022
8:30 am ET	Thinking about buying stock in Finch Therapeutics, Zymeworks, DiDi Global, Bilibili, or IQIYI? InvestorsObserver issues critical PriceWatch Alerts for FNCH, ZYME, DIDI, BILI, and IQ. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)
April 28, 2022
5:24 pm ET	Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today...(Globe Newswire)
April 19, 2022
8:30 am ET	Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today...(Globe Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and